• Je něco špatně v tomto záznamu ?

BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis

E. Punnoose, FV. Peale, E. Szafer-Glusman, G. Lei, R. Bourgon, AD. Do, E. Kim, L. Zhang, P. Farinha, RD. Gascoyne, FJ. Munoz, M. Martelli, A. Mottok, GA. Salles, LH. Sehn, JF. Seymour, M. Trnĕný, MZ. Oestergaard, KE. Mundt, U. Vitolo

. 2021 ; 21 (4) : 267-278.e10. [pub] 20201110

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012482

INTRODUCTION: The prognostic value of B-cell lymphoma 2 (BCL2) expression in de novo diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy is of interest to define a target patient population for clinical development of BCL2 inhibitors. We aimed to develop a reproducible immunohistochemistry algorithm and assay to determine BCL2 protein expression and assess the prognostic value of BCL2 in newly diagnosed DLBCL cohorts. PATIENTS AND METHODS: The prospectively defined algorithm incorporated BCL2 staining intensity and percentage of BCL2-positive cells. Functionally relevant cutoffs were based on the sensitivity of lymphoma cell lines to venetoclax. This assay was highly reproducible across laboratories. The prognostic impact of BCL2 expression was assessed in DLBCL patients from the phase 3 MAIN (n = 230) and GOYA (n = 366) trials, and a population-based registry (n = 310). RESULTS: Approximately 50% of tumors were BCL2 positive, with a higher frequency in high International Prognostic Index (IPI) and activated B-cell-like DLBCL subgroups. BCL2 expression was associated with poorer progression-free survival in the MAIN study (hazard ratio [HR], 1.66; 95% confidence interval [CI], 0.81-3.40; multivariate Cox regression adjusted for IPI and cell of origin). This trend was confirmed in the GOYA and registry cohorts in adjusted multivariate analyses (GOYA: HR, 1.72; 95% CI, 1.05-2.82; registry: HR, 1.89; 95% CI, 1.29-2.78). Patients with BCL2 immunohistochemistry-positive and IPI-high disease had the poorest prognosis: 3-year progression-free survival rates were 51% (GOYA) and 37% (registry). CONCLUSION: Findings support use of our BCL2 immunohistochemistry scoring system and assay to select patients with BCL2-positive tumors for future studies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012482
003      
CZ-PrNML
005      
20220506131003.0
007      
ta
008      
220425s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clml.2020.11.004 $2 doi
035    __
$a (PubMed)33303421
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Punnoose, Elizabeth $u Genentech Inc, South San Francisco, CA. Electronic address: punnoose.elizabeth@gene.com
245    10
$a BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis / $c E. Punnoose, FV. Peale, E. Szafer-Glusman, G. Lei, R. Bourgon, AD. Do, E. Kim, L. Zhang, P. Farinha, RD. Gascoyne, FJ. Munoz, M. Martelli, A. Mottok, GA. Salles, LH. Sehn, JF. Seymour, M. Trnĕný, MZ. Oestergaard, KE. Mundt, U. Vitolo
520    9_
$a INTRODUCTION: The prognostic value of B-cell lymphoma 2 (BCL2) expression in de novo diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy is of interest to define a target patient population for clinical development of BCL2 inhibitors. We aimed to develop a reproducible immunohistochemistry algorithm and assay to determine BCL2 protein expression and assess the prognostic value of BCL2 in newly diagnosed DLBCL cohorts. PATIENTS AND METHODS: The prospectively defined algorithm incorporated BCL2 staining intensity and percentage of BCL2-positive cells. Functionally relevant cutoffs were based on the sensitivity of lymphoma cell lines to venetoclax. This assay was highly reproducible across laboratories. The prognostic impact of BCL2 expression was assessed in DLBCL patients from the phase 3 MAIN (n = 230) and GOYA (n = 366) trials, and a population-based registry (n = 310). RESULTS: Approximately 50% of tumors were BCL2 positive, with a higher frequency in high International Prognostic Index (IPI) and activated B-cell-like DLBCL subgroups. BCL2 expression was associated with poorer progression-free survival in the MAIN study (hazard ratio [HR], 1.66; 95% confidence interval [CI], 0.81-3.40; multivariate Cox regression adjusted for IPI and cell of origin). This trend was confirmed in the GOYA and registry cohorts in adjusted multivariate analyses (GOYA: HR, 1.72; 95% CI, 1.05-2.82; registry: HR, 1.89; 95% CI, 1.29-2.78). Patients with BCL2 immunohistochemistry-positive and IPI-high disease had the poorest prognosis: 3-year progression-free survival rates were 51% (GOYA) and 37% (registry). CONCLUSION: Findings support use of our BCL2 immunohistochemistry scoring system and assay to select patients with BCL2-positive tumors for future studies.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x farmakologie $x terapeutické užití $7 D000971
650    _2
$a nádorové biomarkery $x analýza $x genetika $7 D014408
650    _2
$a klinické zkoušky, fáze III jako téma $7 D017326
650    _2
$a kohortové studie $7 D015331
650    _2
$a chemorezistence $x genetika $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a difúzní velkobuněčný B-lymfom $x farmakoterapie $x genetika $x mortalita $x patologie $7 D016403
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a multicentrické studie jako téma $7 D015337
650    _2
$a prognóza $7 D011379
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a protoonkogenní proteiny c-bcl-2 $x analýza $x genetika $7 D019253
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a registrace $x statistika a číselné údaje $7 D012042
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Peale, Franklin V $u Genentech Inc, South San Francisco, CA
700    1_
$a Szafer-Glusman, Edith $u Genentech Inc, South San Francisco, CA
700    1_
$a Lei, Guiyuan $u Roche Products Limited, Welwyn Garden City, England, United Kingdom
700    1_
$a Bourgon, Richard $u Genentech Inc, South San Francisco, CA
700    1_
$a Do, An D $u Genentech Inc, South San Francisco, CA
700    1_
$a Kim, Eugene $u Genentech Inc, South San Francisco, CA
700    1_
$a Zhang, Liping $u Ventana Medical Systems Inc, Tucson, AZ
700    1_
$a Farinha, Pedro $u Center for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
700    1_
$a Gascoyne, Randy D $u Center for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
700    1_
$a Munoz, F Javier $u F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Martelli, Maurizio $u Department of Translational and Precision Medicine, Hematology Section, Sapienza University, Rome, Italy
700    1_
$a Mottok, Anja $u Center for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada
700    1_
$a Salles, Gilles A $u Department of Hematology, Hospices Civils de Lyon-Université de Lyon, Pierre-Bénite, France
700    1_
$a Sehn, Laurie H $u Center for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada
700    1_
$a Seymour, John F $u Department of Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia; University of Melbourne, Parkville, Victoria, Australia
700    1_
$a Trnĕný, Marek $u Department of Hematology, General Hospital, Charles University, Prague, Czech Republic
700    1_
$a Oestergaard, Mikkel Z $u F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Mundt, Kirsten E $u F. Hoffmann-La Roche Ltd, Basel, Switzerland
700    1_
$a Vitolo, Umberto $u Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy
773    0_
$w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 21, č. 4 (2021), s. 267-278.e10
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33303421 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130955 $b ABA008
999    __
$a ok $b bmc $g 1789896 $s 1163683
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 21 $c 4 $d 267-278.e10 $e 20201110 $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace